Paul Reynolds

Dr. Paul Reynolds is a Lecturer in the Cellular Medicine Division within the School of Medicine at the University of St Andrews. He is affiliated with the Sir James Mackenzie Institute for Early Diagnosis, Centre for Biophotonics, and Biomedical Sciences Research Complex. His research focuses on systems pathology and cancer, with particular emphasis on molecular changes driving disease processes.

Dr. Reynolds' research interests span two primary areas: stromal factors in cancer resistance and factors in placental invasion. His work explores how the tumor microenvironment influences cancer progression and therapy resistance, with specific focus on a novel type I membrane protein expressed on stromal fibroblasts. He also investigates similar invasion mechanisms in placental development, examining how trophoblast cells interact with maternal immune cells during pregnancy. His research employs biochemistry, molecular biology, and cell biology approaches to understand disease mechanisms.

His publication record shows strong focus on kidney disease mechanisms, particularly podocyte function in health and disease, as well as cancer resistance mechanisms in renal cell carcinoma. Recent work has utilized CRISPR/Cas9 screening approaches to identify factors modulating drug sensitivity. His research demonstrates interdisciplinary connections between cancer biology and reproductive biology through shared invasion mechanisms.

Dr. Reynolds actively supervises postgraduate research students, with several thesis projects completed under his supervision. He serves as an external examiner for PhD students at the University of Dundee and holds editorial positions with journals including Frontiers in Physiology and Cancers.

His work contributes to UN Sustainable Development Goals related to health and wellbeing, particularly through research on cancer diagnostics and treatment resistance. Dr. Reynolds maintains active research collaborations as evidenced by his extensive publication record and research projects funded by organizations including the Wellcome Trust.